Przejdź do zawartości
Merck

Upregulated genes at 2q24 gains as candidate oncogenes in hepatoblastomas.

Future oncology (London, England) (2014-12-20)
Tatiane Cristina Rodrigues, Felipe Fidalgo, Cecilia Maria Lima da Costa, Elisa Napolitano Ferreira, Isabela Werneck da Cunha, Dirce Maria Carraro, Ana Cristina Victorino Krepischi, Carla Rosenberg
ABSTRAKT

Cytogenetic data of hepatoblastomas, a rare embryonal tumor of the liver, mostly consist of descriptions of whole-chromosome aneuploidies and large chromosome alterations. High-resolution cytogenetics may provide clues to hepatoblastoma tumorigenesis and indicate markers with clinical significance. We used array-CGH (180K) to screen for genomic imbalances in nine hepatoblastomas. Additionally, we investigated the expression pattern of selected genes exhibiting copy number changes. Analysis showed mainly whole-chromosome or chromosome-arm aneuploidies, but some focal aberrations were also mapped. Expression analysis of 48 genes mapped at one 10 Mb amplification at 2q24 revealed upregulation of DAPL1, ERMN, GALNT5, SCN1A and SCN3A in the set of tumors compared with differentiated livers. These genes appear as candidates for hepatoblastoma tumorigenesis.